【 Top 20 US Stock Turnover: Lilly Weight Loss Drug has a promising outlook, with institutions claiming its stock price will rise by another 20% 】 11th placed US pharmaceutical giant Lilly closed up 4.31%, hitting a new high since November 8, 2023, with a transaction volume of $3.13 billion. According to the latest report from BMO Capital Markets, Lilly's GLP-1 drug Zepbound is expected to dominate the weight loss market in 2024, which will drive the company's stock price up by an additional 20% from its current level. Zepbound was approved by FDA in November last year for long-term weight management of obese or overweight adults with at least one weight related disease (such as high cholesterol, hypertension or type 2 diabetes). The drug was officially launched in December last year.